Vektor Medical

Executive Summary

Vektor Medical is a digital health and medical device company pioneering AI-based non-invasive arrhythmia mapping. Its flagship product, vMap, is an FDA-cleared and CE-marked software platform that analyzes standard 12-lead ECGs to localize the source of cardiac arrhythmias, enabling physicians to plan and execute ablation procedures more efficiently. By providing a non-invasive, rapid, and accurate map of arrhythmia origins, vMap aims to reduce procedure times, improve success rates, and minimize patient risk. The company, founded in 2018 and headquartered in Carlsbad, California, is positioned at the intersection of cardiovascular care, medical devices, and digital health. With vMap's regulatory clearances already obtained, Vektor Medical is focused on commercial adoption and generating clinical evidence to support widespread use in electrophysiology labs worldwide. The platform's potential to streamline workflows and enhance patient outcomes addresses a significant unmet need in the treatment of complex arrhythmias such as atrial fibrillation and ventricular tachycardia, which affect millions of patients globally. As healthcare systems increasingly prioritize efficiency and precision, vMap offers a compelling value proposition by replacing or augmenting invasive mapping techniques with a cloud-based, AI-driven solution. The company's early traction and regulatory milestones suggest a strong foundation, but broader market adoption will depend on continued clinical validation, competitive differentiation, and strategic partnerships. Overall, Vektor Medical represents a promising innovation in cardiac electrophysiology with the potential to transform standard of care for ablation procedures.

Upcoming Catalysts (preview)

• Q3 2026Publication of pivotal clinical trial results demonstrating improved ablation outcomes with vMap70% success
• Q4 2026Strategic partnership with a leading electrophysiology device manufacturer or hospital network60% success
• Q2 2026Series A or B funding round to expand commercial operations and clinical studies75% success